U404 Foot Valve
Materials:
Body: Brass
Valve: Brass
Seal : Buna-N / Viton
Features :
Valve closing speed:0.5S
Medium: Gasoline, diesel , and kerosene
Operating Temperature: -30~~+55degree
U404 Series Foot Valves are installed on the bottom of suction tubes in the fuel storage tank to maintain prime in suction system fuel lines.
Double-poppet models provide redundant protection for holding the prime, and are ideal for installations where the valve is not easily accessible.
U404 Series Foot Valves feature precision metal-to-metal sealing arrangements.U404 Series Foot Valves are recommended for use on suction lines where the pressure does not exceed 34 ft of head (approximately 15 psi).
U404 Series Foot Valves are pressured tested to ensure accuracy
Screen protects the valve from debris
100% Factory Tested.
Package:
Net Weight Cross Weight Dimension
32kg/case of 20 35kg/case of 20 30x31.2x18.5cm/case of 20
Important:
The products should be used in compliance with applicable country, province and local Laws and regulations. Products selection should be based on physical Specifications and limitations and compatibility with the environmentand materials to be handled. HONGYANG makes no warranty of fitness for a particular use. All illustrations and Specifications in this literature are based on the latest products information available at the time of publication,HONGYANG reserves the right to make changes at any time in price, materials. Specifications and models and to discontinue models without notice or obligation.
we are committed to create the best workplace, encourage our staffs to put their own personalities into their jobs, and provide them a stage to show themselves.
ltana s â‚?.5 billion takeover also fell short of expectations.
However, Patri fuel dispenser ck Schwarz-Schütte, the boss of Schwarz and the founder s son, quickly came to an
agreement with UCB. He sold for â‚?.4 billion, a healthy price, without inviting other bidders. Schwarz is
about to launch Lacosamide, a treatment for epilepsy, which will come in handy when Keppra, UCB s
successful epilepsy drug, comes off its patent. Schwarz s Neupro, a patch to treat Parkinson s disease,
has been launched in Europe and was recently approved for use in America. “What matters is
innovation,�says Mr Doliveux.
UCB itself is a middle-sized company, controlled by the heirs of Emmanuel Janssen, who founded the firm
in 1928. Both companies concentrate mostly on treating diseases of the nervous system. UCB has a
distribution network to help Schwarz push its new products, especially in America. The firms will have a
combined R&D budget of â‚?70m a year. Neither wants to be swallowed by an industry giant, such as
America s Pfizer or Switzerland s Novartis.
In a sign of confidence in UCB s management, the Schwarz-Schüttes will keep a 40% stake in the new
company. Patrick Schwarz-Schütte will join the UCB board. Most analysts like the deal, although some
worry about future profits. Schwarz relies for almost one-fifth of its sales, and a greater proportion of its
profits, on Omeprazole, an anti-ulcer drug, which in 2009 loses its already limited patent protection. For
the time being the company enjoys payments for a licence for Fesoterodine, an incontinence drug, from
Pfizer. However, these will stop in 2008.
Yet size does help in marketing and distribution, and the new UCB will remain fuel dispenser smaller than the industry s
giants. Size can also benefit R&D. Firms with big budgets and better laboratories are said to attract more
talented researchers. However, others argue that corporate titans can kill the entrepreneurial spirit and
flexibility that fosters great discoveries. GlaxoSmithKline, a British drugs giant, has cr fuel dispenser
